Clinical Trial: A Phase 2, Open-Label, Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07904767) titled 'A Phase 2, Open-Label, Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis' on Oct. 23.

Brief Summary: The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to placebo, and to establish that the therapeutic is safe and generally well tolerated by patients.

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Blepharitis

Intervention: DRUG: APT-001 topical ophthalmic ointment (spinosad)

APT-001 topical ophthalmic ointment (spinosad), administered once

DR...